inclusion criteria: 1. male or female subjects aged ≥ 18 years when signing the informed consent form (icf); 2. subjects with reverse transcription-polymerase chain reaction (rt-pcr) test positive for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) in specimens such as nasopharyngeal swabs/oropharyngeal swabs for the first time within 4 days prior to randomization who meet the diagnostic and treatment criteria for mild and moderate cases in the diagnosis and treatment protocol for covid-19 (trial version 9) issued by the national health commission of the peoples republic of china ; 3. rt-pcr result of n gene or orf gene of sars-cov-2 within 48 hours before randomization shows a ct value \< 35; at least 2 covid-19 target symptoms appeared for the first time within 72 hours before randomization (covid-19 target symptoms include fever, cough, stuffy or runny nose, sore throat or dry throat, shortness of breath or difficulty breathing, headache, muscle or body aches, diarrhoea, chills, nausea, and vomit), including at least one designated symptom: fever, cough, stuffy or runny nose, sore throat or dry throat, shortness of breath or difficulty breathing; 4. women of childbearing potential must have a negative serum pregnancy test during the screening period. subjects should take effective contraceptive measures throughout the study period since signing the informed consent form and for 28 days after the end of the study; 5. subjects who are able to understand the study procedures and methods, and voluntarily participate in the study and sign the icf after being fully informed.

inclusion criteria: 1. male or female subjects aged ≥ 18 years when signing the informed consent form (icf); 2. subjects with reverse transcription-polymerase chain reaction (rt-pcr) test positive for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) in specimens such as nasopharyngeal swabs/oropharyngeal swabs for the first time within 4 days prior to randomization who meet the diagnostic and treatment criteria for mild and moderate cases in the diagnosis and treatment protocol for covid-19 (trial version 9) issued by the national health commission of the peoples republic of china ; 3. rt-pcr result of n gene or orf gene of sars-cov-2 within 48 hours before randomization shows a ct value \< 35; at least 2 covid-19 target symptoms appeared for the first time within 72 hours before randomization (covid-19 target symptoms include fever, cough, stuffy or runny nose, sore throat or dry throat, shortness of breath or difficulty breathing, headache, muscle or body aches, diarrhoea, chills, nausea, and vomit), including at least one designated symptom: fever, cough, stuffy or runny nose, sore throat or dry throat, shortness of breath or difficulty breathing; 4. women of childbearing potential must have a negative serum pregnancy test during the screening period. subjects should take effective contraceptive measures throughout the study period since signing the informed consent form and for 28 days after the end of the study; 5. subjects who are able to understand the study procedures and methods, and voluntarily participate in the study and sign the icf after being fully informed.

inclusion criteria: male or female subjects aged ≥ 18 years when signing the informed consent form (icf); subjects with reverse transcription-polymerase chain reaction (rt-pcr) test positive for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) in specimens such as nasopharyngeal swabs/oropharyngeal swabs for the first time within 4 days prior to randomization who meet the diagnostic and treatment criteria for mild and moderate cases in the diagnosis and treatment protocol for covid-19 (trial version 9) issued by the national health commission of the peoples republic of china ; rt-pcr result of n gene or orf gene of sars-cov-2 within 48 hours before randomization shows a ct value < 35; at least 2 covid-19 target symptoms appeared for the first time within 72 hours before randomization (covid-19 target symptoms include fever, cough, stuffy or runny nose, sore throat or dry throat, shortness of breath or difficulty breathing, headache, muscle or body aches, diarrhoea, chills, nausea, and vomit), including at least one designated symptom: fever, cough, stuffy or runny nose, sore throat or dry throat, shortness of breath or difficulty breathing; women of childbearing potential must have a negative serum pregnancy test during the screening period. subjects should take effective contraceptive measures throughout the study period since signing the informed consent form and for 28 days after the end of the study; subjects who are able to understand the study procedures and methods, and voluntarily participate in the study and sign the icf after being fully informed.

inclusion criteria: male or female subjects aged ≥ 18 years when signing the informed consent form (icf); subjects with reverse transcription-polymerase chain reaction (rt-pcr) test positive for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) in specimens such as nasopharyngeal swabs/oropharyngeal swabs for the first time within 4 days prior to randomization who meet the diagnostic and treatment criteria for mild and moderate cases in the diagnosis and treatment protocol for covid-19 (trial version 9) issued by the national health commission of the peoples republic of china ; rt-pcr result of n gene or orf gene of sars-cov-2 within 48 hours before randomization shows a ct value < 35; at least 2 covid-19 target symptoms appeared for the first time within 72 hours before randomization (covid-19 target symptoms include fever, cough, stuffy or runny nose, sore throat or dry throat, shortness of breath or difficulty breathing, headache, muscle or body aches, diarrhoea, chills, nausea, and vomit), including at least one designated symptom: fever, cough, stuffy or runny nose, sore throat or dry throat, shortness of breath or difficulty breathing; women of childbearing potential must have a negative serum pregnancy test during the screening period. subjects should take effective contraceptive measures throughout the study period since signing the informed consent form and for 28 days after the end of the study; subjects who are able to understand the study procedures and methods, and voluntarily participate in the study and sign the icf after being fully informed.

inclusion criteria: participants ≥18 years of age. confirmed sars-cov-2 infection 4 days prior to randomization. the subjects were classified as mild/moderate type covid-19. initial onset 2 of 11 covid-19 symptoms within 48 hours before randomization,respiratory and feverish symptoms must be included. participants who are willing and able to comply with the protocol for treatment plan, virological testing, laboratory testing and other study procedures. fertile participants must agree to take effective contraceptive measures.

inclusion criteria: participants ≥18 years of age. confirmed sars-cov-2 infection 4 days prior to randomization. the subjects were classified as mild/moderate type covid-19. initial onset 2 of 11 covid-19 symptoms within 48 hours before randomization,respiratory and feverish symptoms must be included. participants who are willing and able to comply with the protocol for treatment plan, virological testing, laboratory testing and other study procedures. fertile participants must agree to take effective contraceptive measures.